- Conditions
- Coronary Artery Disease
- Interventions
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 83
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
- Interventions
- [18F]FluorbetaOx
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chest Pain, Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Kettering Health Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Kettering, Ohio
- Conditions
- Coronary Artery Disease
- Interventions
- BFPET
- Drug
- Lead sponsor
- Fluoropharma, Inc.
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Coronary Artery Disease
- Interventions
- Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement
- Radiation
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson Disease (PD), Lewy Body Dementia (LBD)
- Interventions
- 18F-MFBG
- Drug
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Diseases
- Interventions
- L-NAME, L-Arginine, Phenylephrine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronary Artery Disease
- Interventions
- Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT, Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
- Drug
- Lead sponsor
- Cardiovascular Imaging Technologies
- Industry
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Heart Failure, Nonischemic Dilated Cardiomyopathy
- Interventions
- spironolactone
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Coronary Artery Disease
- Interventions
- Myocardial perfusion imaging
- Procedure
- Lead sponsor
- Aspire Foundation
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Ischemia
- Interventions
- BMS747158
- Drug
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Fremont, California • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
- Interventions
- 68Ga-FAP-2286, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Coronary Artery Disease
- Interventions
- Antigravity treadmill (Alter-G), Conventional treadmill/regadenoson
- Device
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Myocardial Perfusion Imaging, Myocardial Ischemia
- Interventions
- Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
- Drug · Procedure · Behavioral
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
- Conditions
- Pulmonary Arterial Hypertension, Healthy
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cardiac Sarcoidosis, Myocardial Inflammation
- Interventions
- 18F-FSPG
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Obesity, Heart Failure
- Interventions
- PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose
- Procedure · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronary Artery Disease
- Interventions
- Apadenoson
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Timeline
- 2006
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more
- Conditions
- Coronary Artery Disease
- Interventions
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 863 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
- Conditions
- Myocardial Blood Flow Reserve
- Interventions
- Regadenoson, Rubidium-82
- Drug · Radiation
- Lead sponsor
- Timothy M. Bateman, MD
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Ischemic Cardiomyopathy, Hibernating Myocardium, Nerve; Disorder, Sympathetic
- Interventions
- Positron Emission Tomography
- Radiation
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Drug · Procedure
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
- Conditions
- Coronary Artery Disease
- Interventions
- PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia